ANGLE plc (ANPCF)

ANGLE plc is a British diagnostics company that isolates circulating tumor cells from blood samples to help oncologists understand cancer progression and tailor treatment. Founded in 2006 and listed on US OTC markets under the ticker ANPCF, the company has developed a proprietary platform called Parsortix that uses microfiltration to capture cancer cells shedding into the bloodstream. Rather than relying on tissue biopsies—which are invasive, infrequent, and may not capture tumor heterogeneity—ANGLE’s approach enables clinicians to sample blood repeatedly throughout a patient’s treatment journey. This “liquid biopsy” model addresses a core challenge in oncology: obtaining current tumor material for genetic testing and treatment selection without subjecting patients to repeated procedures.

The company’s technology occupies a specific niche within the broader liquid biopsy field. While many competitors focus on detecting cell-free tumor DNA (fragments of genetic material floating in blood), ANGLE isolates intact circulating tumor cells themselves. Once captured, these cells can be analyzed for genetic mutations, protein expression, and other biomarkers that inform which drugs are most likely to work. Pharmaceutical and biotech firms increasingly use Parsortix in clinical trials to monitor treatment response in real time, and hospitals and cancer research centers have adopted the system for clinical use and investigational purposes. Revenue flows from instrument sales and leases, as well as recurring consumables—the microfluidic cartridges and reagents required for each test.

Adoption in clinical laboratories and oncology centers remains the key growth lever. Broader hospital integration depends on demonstrating clinical utility through published studies, obtaining regulatory approvals that enable reimbursement, and forming partnerships that embed Parsortix into standard cancer care workflows. The landscape is competitive; larger diagnostics companies, academic institutions, and well-funded liquid biopsy startups are all pursuing related technologies. ANGLE’s success rests on establishing a defensible evidence base for its platform and building a durable installed base of systems generating recurring cartridge sales.

Investors can examine the company’s trajectory through SEC filings (CIK 1620678), which detail revenue drivers, adoption metrics, and risk factors. Peer-reviewed publications and clinical evidence for Parsortix utility, along with investor relations announcements of new partnerships and regulatory milestones, provide texture on market penetration and competitive positioning. Industry analyst reports on the liquid biopsy and precision oncology markets help contextualize ANGLE’s addressable opportunity and competitive standing.